Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ProQR Therapeutics N.V.PRQR · Entity 5946 | Chief Financial Officer | March 18, 2026 | March 18, 2026 |
| Sagimet Biosciences Inc.SGMT · Entity 5273 | Chief Financial Officer | July 18, 2023 | July 20, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ProQR Therapeutics N.V.
Report date March 18, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.66 · Expires 2035-04-30 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: 25% of the shares subject to such option vest and become exercisable on May 1, 2026, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.02 · Expires 2035-12-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: 25% of the shares subject to such option vest and become exercisable on January 1, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to such option vest and become exercisable on May 1, 2026, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
F2: 25% of the shares subject to such option vest and become exercisable on January 1, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
Sagimet Biosciences Inc.
Report date July 18, 2023 · Filed July 20, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.36 · Expires 2029-04-27 | Direct | 0 |
Reported balance
After 2023-07-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-07-18 · Disposition to issuer · Disposed 111,438 · Balance 0 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2: The shares underlying this option are fully vested and exercisable as of the date hereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.36 · Expires 2029-04-27 | Direct | 111,438 |
Reported balance
After 2023-07-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-07-18 · Grant · Acquired 111,438 · Balance 111,438 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2: The shares underlying this option are fully vested and exercisable as of the date hereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.36 · Expires 2029-04-27 | Direct | 0 |
Reported balance
After 2023-07-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-07-18 · Disposition to issuer · Disposed 9,286 · Balance 0 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2: The shares underlying this option are fully vested and exercisable as of the date hereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.36 · Expires 2029-04-27 | Direct | 9,286 |
Reported balance
After 2023-07-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-07-18 · Grant · Acquired 9,286 · Balance 9,286 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2: The shares underlying this option are fully vested and exercisable as of the date hereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.36 · Expires 2031-01-26 | Direct | 0 |
Reported balance
After 2023-07-18 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-07-18 · Disposition to issuer · Disposed 136,846 · Balance 0 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F3: The shares underlying this option shall vest in forty-eight (48) equal monthly installments following January 27, 2021, subject to the Reporting Person's continued service on each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.36 · Expires 2031-01-26 | Direct | 136,846 |
Reported balance
After 2023-07-18 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-07-18 · Grant · Acquired 136,846 · Balance 136,846 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F3: The shares underlying this option shall vest in forty-eight (48) equal monthly installments following January 27, 2021, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.
F2: The shares underlying this option are fully vested and exercisable as of the date hereof.
F3: The shares underlying this option shall vest in forty-eight (48) equal monthly installments following January 27, 2021, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 18, 2023 Filed Jul 20, 2023 20:16 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 136,846 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001104659-23-082724 · tm2321276-15_4seq1.xml · derivative · entry 6 Hom Dennis · CIK 0001600362 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,846 Underlying: Series A Common Stock · 136,846 shares Expires 2031-01-26 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F3 · derivative.exercise_date: The shares underlying this option shall vest in forty-eight (48) equal monthly installments following January 27, 2021, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:16 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Disposition to issuerStock Option (Right to Buy) · Derivative | 136,846 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001104659-23-082724 · tm2321276-15_4seq1.xml · derivative · entry 5 Hom Dennis · CIK 0001600362 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 136,846 shares Expires 2031-01-26 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F3 · derivative.exercise_date: The shares underlying this option shall vest in forty-eight (48) equal monthly installments following January 27, 2021, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:16 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 9,286 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001104659-23-082724 · tm2321276-15_4seq1.xml · derivative · entry 4 Hom Dennis · CIK 0001600362 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,286 Underlying: Series A Common Stock · 9,286 shares Expires 2029-04-27 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable as of the date hereof. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:16 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Disposition to issuerStock Option (Right to Buy) · Derivative | 9,286 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001104659-23-082724 · tm2321276-15_4seq1.xml · derivative · entry 3 Hom Dennis · CIK 0001600362 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,286 shares Expires 2029-04-27 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable as of the date hereof. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:16 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 111,438 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001104659-23-082724 · tm2321276-15_4seq1.xml · derivative · entry 2 Hom Dennis · CIK 0001600362 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,438 Underlying: Series A Common Stock · 111,438 shares Expires 2029-04-27 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable as of the date hereof. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:16 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Disposition to issuerStock Option (Right to Buy) · Derivative | 111,438 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001104659-23-082724 · tm2321276-15_4seq1.xml · derivative · entry 1 Hom Dennis · CIK 0001600362 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 111,438 shares Expires 2029-04-27 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable as of the date hereof. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.